Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$531.2MCash, Jun 2026
20moCash Runway (est.)
Follow EIKN by emailGet an email when EIKN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EIKN, unsubscribe in one click. Privacy
📣 What EIKN Says Is Next
by the end of 2026 · “EIK1006: Expects to submit an IND by the end of 2026.”
Company press release, Aug 13, 2026 · SEC filing
by the end of 2026 · “Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026.”
Company press release, Aug 13, 2026 · SEC filing
2H 2026 · “Initiation of Cohort 1D, combining EIK1003 with platinum and paclitaxel therapy in breast and ovarian cancer treatment is anticipated in 2H 2026.”
Company press release, Mar 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
EIKN reported $531.2M in cash and short-term investments (as of Jun 30, 2026) and used about $78M/quarter in operations, an estimated runway of 20.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:16 · Low
Cash runway 20 months +8
S-1 registration (Jan 2026) +8
Recent financing filings on SEC EDGAR:
Feb 5, 2026 · Underwritten offering, $381M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EIKN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.